Ruth Hyland

Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction.

Alex Phipps, R Scott Obach, Maurice Dickins, 2008, British journal of clinical pharmacology.

Optimized Assays for Human UDP-Glucuronosyltransferase (UGT) Activities: Altered Alamethicin Concentration and Utility to Screen for UGT Inhibitors

J. Bauman, R. Walsky, R. Obach, 2012, Drug Metabolism and Disposition.

Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring.

Hendrik Neubert, T. Goosen, H. Neubert, 2013, Journal of proteome research.

DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS

Barry C. Jones, Jeffrey R. Koup, Dennis A. Smith, 2004, Drug Metabolism and Disposition.

Understanding CYP2D6 interactions.

M. D. de Groot, G. Whitlock, Florian Wakenhut, 2009, Drug discovery today.

Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction

Alex Phipps, Kuresh Youdim, Maurice Dickins, 2009, Drug Metabolism and Disposition.

Maraviroc: in vitro assessment of drug-drug interaction potential.

Maurice Dickins, Claire Collins, B. Jones, 2008, British journal of clinical pharmacology.

Utility of human/human-derived reagents in drug discovery and development: An industrial perspective.

H. van de Waterbeemd, B. Jones, R. Hyland, 2006, Environmental toxicology and pharmacology.